Report

Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.

Asset 41 2
160 1608792 circle document icon png transparent png

North America Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)   

The influenza vaccines market in North America is expected to grow from US$ 3,155.29 million in 2022 to US$ 4,909.00 million by 2028. It is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

Increasing Investment by Top Market Players and Governments

Market players and governments are increasing their investments in vaccine development and immunization. For instance, In March 2021, Sanofi announced an approximately US$ 925 million investment in a new vaccine manufacturing plant at its pre-existing site in Toronto and Canada. Investments in the new facility will provide additional antigen and filling capacity for Sanofi’s FLUZONE high-dose quadrivalent influenza vaccines, increasing availability in Canada, the US in the years to come. In addition, Sanofi will also invest at least US$ 79 million annually over 8 years to fund research and development in Canada. Thus, the increase in investment by top market players and governments across the region is bolstering the influenza vaccines market.

Market Overview

The North America influenza vaccines market has been segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2021. The rising number of flu cases, growing research & development activities on flu vaccines, and rising demand for advanced vaccines to prevent diseases are among the prominent factors propelling the market growth in this region. The US accounts for a significant share of the influenza vaccines market in North America. The rising number of flu cases in the US is likely to increase the demand of influenza vaccines. As per the Centers for Disease Control and Prevention (CDC), in the US, from 2010 to 2020, flu led to illnesses between 9 million and 41 million annually. Also increasing number of flu vaccinations is likely to enhance the market growth. As per the CDC, as of April 2021, an around 47.7 million adult flu vaccinations were administered in pharmacies compared with 35.4 million at the same time in 2020 which is 35% higher.

Also, national campaigns focused on influenza vaccinations are likely to enhance market growth. For instance, during the pandemic, the National Forum for Heart Disease & Stroke Prevention initiated ‘Move with the Mayor Flu Vaccination Campaign’ where the mayors are protecting their communities from the dual threat of COVID-19 and flu by encouraging people to get vaccinated for flu. Additionally, US pharmaceutical market is the largest and the most commercial market in North America. The United States alone holds over 45% of the global pharmaceutical market

North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

North America Influenza Vaccines Market Segmentation

The North America influenza vaccines market is segmented into vaccine type, virus type, technology, route of administration, and country.

Based on vaccine type, the North America influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.

Based on virus type, the North America influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.

Based on technology, the North America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.

Based on route of administration, the North America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.

Based on country, the market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2022.

AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in North America.

TABLE OF CONTENTS

1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Influenza Vaccines Market – By Vaccine Type
1.3.2 North America Influenza Vaccines Market – By Virus Type
1.3.3 North America Influenza Vaccines Market – By Technology
1.3.4 North America Influenza Vaccines Market – By Route Of Administration
1.3.5 North America Influenza Vaccines Market – By Country
2. North America Influenza Vaccines Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Influenza Vaccines Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. North America Influenza Vaccines Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Government Support to Promote Influenza Vaccination
5.1.2 Increasing Investment by Top Market Players and Governments
5.2 Market Restraints
5.2.1 High Cost of Vaccine Development
5.3 Market Opportunities
5.3.1 Emerging Economies
5.4 Future Trends
5.4.1 Strong Pipeline Candidates for Influenza Vaccines
5.5 Impact Analysis
6. Influenza Vaccine Market – North America Analysis
6.1 North America Influenza Vaccines Market Revenue Forecasts And Analysis
7. North America Influenza Vaccines Market– By Vaccine Type
7.1 Overview
7.2 North America Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
7.3 Quadrivalent Vaccines
7.3.1 Overview
7.3.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Trivalent Vaccines
7.4.1 Overview
7.4.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
8. North America Influenza Vaccines Market– By Virus Type
8.1 Overview
8.2 North America Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
8.3 Influenza Virus Type A
8.3.1 Overview
8.3.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Influenza Virus Type B
8.4.1 Overview
8.4.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
9. North America Influenza Vaccines Market – By Technology
9.1 Overview
9.2 North America Influenza Vaccines Market, By Technology 2022 & 2028 (%)
9.3 Egg-Based
9.3.1 Overview
9.3.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Cell-Based
9.4.1 Overview
9.4.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
10. North America Influenza Vaccines Market– By Route of Administration
10.1 Overview
10.2 North America Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
10.3 Injection
10.3.1 Overview
10.3.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Nasal Spray
10.4.1 Overview
10.4.2 North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
11. North America Influenza Vaccines Market – Country Analysis
11.1 North America Influenza Vaccines Market Revenue and Forecasts to 2028
11.1.1 Overview
11.1.2 North America: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
11.1.2.1 US: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.1 Overview
11.1.2.1.2 US: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.3 US: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
11.1.2.1.4 US: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
11.1.2.1.5 US: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
11.1.2.1.6 US: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.2.2 Canada: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.1 Overview
11.1.2.2.2 Canada: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.3 Canada: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
11.1.2.2.4 Canada: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
11.1.2.2.5 Canada: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
11.1.2.2.6 Canada: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.2.3 Mexico: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.1 Overview
11.1.2.3.2 Mexico: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.3 Mexico: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
11.1.2.3.4 Mexico: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
11.1.2.3.5 Mexico: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
11.1.2.3.6 Mexico: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
12. North America Influenza Vaccine Market –Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Moderna, Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 SEQIRUS
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sanofi
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 GlaxoSmithKline plc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Hualan Biological Engineering Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Emergent BioSolutions Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Mitsubishi Chemical Group Corporation
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Serum Institute of India Pvt. Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 MYLAN N.V.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 AstraZeneca
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms

LIST OF TABLES

Table 1.             North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
Table 2.             US Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
Table 3.             US Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
Table 4.             US Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 5.             US Influenza Vaccines Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 6.             Canada Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
Table 7.             Canada Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
Table 8.             Canada Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 9.             Canada Influenza Vaccines Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 10.          Mexico Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
Table 11.          Mexico Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
Table 12.          Mexico Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 13.          Mexico Influenza Vaccines Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 14.          Recent Inorganic Growth Strategies in the North America Influenza Vaccine Market
Table 15.          Recent Organic Growth Strategies in the North America Influenza Vaccine Market
Table 16.          Glossary of Terms, North America Influenza Vaccines Market
 
 

LIST OF FIGURES

Figure 1.           North America Influenza Vaccines Market Segmentation
Figure 2.           North America Influenza Vaccines Market Segmentation, by Country
Figure 3.           North America Influenza Vaccines Market Overview
Figure 4.           Quadrivalent Vaccines Segment Held Largest Share of Product Segment in North America Influenza Vaccines Market
Figure 5.           US Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7.           North America: PEST Analysis
Figure 8.           Experts Opinion
Figure 9.           Impact Analysis
Figure 10.        North America Influenza Vaccines Market – Revenue Forecasts and Analysis – 2020- 2028
Figure 11.        North America Influenza Vaccines Market, by Vaccine Type 2022 & 2028 (%)
Figure 12.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14.        North America Influenza Vaccines Market, by Virus Type 2022 & 2028 (%)
Figure 15.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17.        North America Influenza Vaccines Market, by Technology 2022 & 2028 (%)
Figure 18.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 20.        North America Influenza Vaccines Market, by Route of Administration 2022 & 2028 (%)
Figure 21.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22.        North America Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 23.        North America: Influenza Vaccines Market, by Key Country – Revenue (2022) (US$ Million)
Figure 24.        North America: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
Figure 25.        US: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26.        Canada: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27.        Mexico: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America Influenza Vaccines Market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the North America Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the Influenza Vaccines Market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

The List of Companies – North America Influenza Vaccines Market

● AstraZeneca
● Emergent BioSolutions Inc.
● GlaxoSmithKline plc.
● Hualan Biological Engineering Inc.
● Mitsubishi Chemical Group Corporation
● Moderna, Inc.
● MYLAN N.V.
● Sanofi
● SEQIRUS
● Serum Institute of India Pvt. Ltd

Pricing

$3,000.00$5,000.00

Have a Query?

Have a Question?

Related Reports

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

GET FREE SAMPLE PDF

× Enquire Now